论文部分内容阅读
目的探讨女性和非吸烟的肺腺癌标本中表皮生长因子受体(EGFR)过表达与EG- FR基因突变的关系。方法应用组织微阵列和免疫组织化学方法检测137例国人非小细胞肺癌标本(鳞癌71例、腺癌66例)中EGFR的表达,采用测序的方法检测EGFR基因突变。结果EG- FR过表达率在肺鳞癌中为63.4%显著高于腺癌的43.9%(P<0.05),其与性别、吸烟情况无关,也与基因突变无关。结论EGFR的过表达率在女性、非吸烟、腺癌及存在EGFR突变的标本中未见升高,提示这些人群中EGFR抑制剂效果较好的原因与蛋白过表达无关。
Objective To investigate the relationship between epidermal growth factor receptor (EGFR) overexpression and mutations of EG-FR gene in female and non-smoking lung adenocarcinoma specimens. Methods Tissue microarray and immunohistochemistry were used to detect the expression of EGFR in 137 Chinese NSCLC patients (71 squamous cell carcinomas and 66 adenocarcinomas). The EGFR gene mutations were detected by sequencing. Results The overexpression of EG-FR in lung squamous cell carcinoma was 63.4%, which was significantly higher than that in adenocarcinoma (43.9%) (P <0.05). The overexpression rate of EG-FR was not related to sex and smoking, nor to gene mutation. Conclusion The overexpression rate of EGFR in women, non-smoking, adenocarcinoma and EGFR mutation specimens showed no increase, suggesting that the reason why EGFR inhibitors are better in these populations is not related to protein overexpression.